The company said in a post on LinkedIn that doctors at the Ottawa Heart Institute completed the first commercial case with Varipulse. J&J said the procedure “marks a significant step forward” in the treatment of AFib with the pulsed field ablation (PFA) technology.

“A huge thank you to the Ottawa Heart Institute for their partnership in bringing this groundbreaking treatment to Canada,” the company wrote. “Together, we’re committed to advancing cardiac arrhythmia management and helping those with this condition live the lives they want.”